Since 2013, the arthropod-borne Chikungunya virus (CHIKV) has cocirculated with the autochthonous Mayaro virus (MAYV) in Latin America. Both belong to the same alphavirus serocomplex, termed the Semliki Forest serocomplex. The extent of antibody cross-reactivity due to the antigenic relatedness of CHIKV and MAYV in commonly used serologic tests remains unclear. By testing 64 CHIKV-and 37 MAYV-specific sera from cohort studies conducted in Peru and Brazil, we demonstrate about 50% false-positive test results using commercially available enzymelinked immunosorbent assays (ELISAs) based on structural antigens. In contrast, combining ELISAs for CHIKV and MAYV significantly increased positive predictive values (PPV) among all cohorts from 35.3% to 88.2% for IgM and from 61.3% to 96.8% for IgG (P Ͻ 0.0001). Testing of longitudinally collected CHIKV-specific patient sera indicated that ELISA specificity is highest for IgM testing at 5 to 9 days post-onset of symptoms (dpo) and for IgG testing at 10 to 14 dpo. IgG cross-reactivity in ELISA was asymmetric, occurring in 57.9% of MAYV-specific sera compared to 29.5% of CHIKV-specific sera. Parallel plaque reduction neutralization testing (PRNT) for CHIKV and MAYV increased the PPV from 80.0% to 100% (P ϭ 0.0053). However, laborintense procedures and delayed seroconversion limit PRNT for patient diagnostics. In sum, individual testing for CHIKV or MAYV only is prone to misclassifications that dramatically impact patient diagnostics and sero-epidemiologic investigation. Parallel ELISAs for both CHIKV and MAYV provide an easy and efficient solution to differentiate CHIKV from MAYV infections. This approach may provide a template globally for settings in which alphavirus coemergence imposes similar problems.
neutralization was also observed, albeit at lower frequencies. Parallel testing for both viruses and comparison of ELISA reactivities and neutralizing antibody titers significantly increased diagnostic specificity. Our data provide a convenient and practicable solution to ensure robust differentiation of CHIKV-and MAYV-specific antibodies. KEYWORDS cross-reactivity, arbovirus diagnostics, serology, Brazil, Peru, ELISA, mosquito-borne disease, outbreak S ince 1955, Mayaro virus (MAYV) infections have been reported in Latin America, predominantly from the Amazon Basin (1, 2) . In recent years, MAYV emergence in areas of previous nonendemicity has been observed (2, 3) . Around 2013, Chikungunya virus (CHIKV) emerged in the Americas, infecting millions of individuals as of today (4) . CHIKV and MAYV are both alphaviruses belonging to the Semliki Forest serocomplex ( Fig. 1A) , in which antibody cross-recognition of heterologous antigens can occur due to relatively high translated sequence identity between the protein-coding genomic domains ( Fig. 1B) (5) . As alphavirus viremia is short-lived, serologic detection of virus-specific antibodies is required for patient diagnostics and sero-epidemiologic studies (6, 7) . Diagnostics in public health laboratories demand robust high-throughput tests, such as enzyme-linked immunosorbent assays (ELISAs) (7) . To systematically assess serologic testing of MAYV and CHIKV, we assembled a panel comprising 37 MAYV-specific sera from Peru and 64 CHIKV-specific sera from Brazil (8), including longitudinally collected samples (6) ( Table 1 ). Samples were tested using ELISA kits relying on comparable structural antigens that are widely used in Latin America (Euroimmun, Luebeck, Germany) (9, 10).
Alphavirus-specific IgM detection is important for patient diagnostics and incidence estimates during surveillance (6, 11) . Among IgM-positive sera in this study, 64.7% were ELISA positive for both CHIKV and MAYV. Cross-reactivities were comparable for CHIKV-specific (63.6%) ( Fig. 1C ) and MAYV-specific (66.7%) ( Fig. 1D ) sera. Detection of IgG is key for testing of convalescent-phase sera and in epidemiologic studies. Compared to that of IgM-positive sera, cross-reactivity was significantly lower among IgG-positive sera, of which 38.1% were ELISA positive for both viruses (P ϭ 0.0081, Fisher's exact test). IgG cross-reactivity in ELISA was not symmetric. A total of 29.5% of the CHIKV-specific ( Fig. 1E ) and 57.9% of the MAYV-specific sera ( Fig. 1F ) yielded positive test results for both viruses (P ϭ 0.0484, Fisher's exact test). An individual ELISA for CHIKV-or MAYV-specific antibodies, particularly for IgM, is thus not reliable in regions with CHIKV and MAYV cocirculation, as high rates of false-positive results must be expected.
Antibody maturation over time may affect the level of cross-reactivity in serologic tests (12) . To examine how antibody cross-reactivity changes over time, longitudinally collected CHIKV-specific sera were tested. Using ELISA, CHIKV IgM reactivity increased rapidly, with a peak at 10 to 14 days post-onset of symptoms (dpo) ( Fig. 1G ). CHIKV IgG reactivity increased steadily, with 100% seroconversion at 90 dpo ( Fig. 1H) (6) . Contrarily to what was expected, decreasing cross-reactivity over time as a consequence of antibody maturation was not observed. Although MAYV ELISA reactivity was lower than that for CHIKV, the trends of CHIKV-specific ELISA reactivity and cross-reactive MAYV ELISA reactivity were identical for both IgM and IgG, suggesting that cross-reactivity was correlated with CHIKV-specific ELISA reactivity. To examine this potential correlation, we performed linear regression analyses. For both CHIKV-and MAYV-specific sera, IgM ELISA cross-reactivity correlated significantly with virus-specific IgM ELISA reactivity (P Ͻ 0.0001), explaining 57.7% of the observed variance ( Fig. 1I) . Similarly, IgG ELISA cross-reactivity correlated with virus-specific ELISA reactivity (P ϭ 0.0001), explaining 21.2% of the observed variance (Fig. 1J ). The risk of false-positive ELISA results, particularly for IgM, thus increases with increasing virus-specific ELISA reactivity.
Plaque reduction neutralization testing (PRNT) is the gold standard for arbovirus serology. Testing of longitudinal CHIKV samples showed steadily increasing CHIKVspecific PRNT titers, peaking at 90 dpo. Cross-neutralization of MAYV was rare and occurred more often with increasing CHIKV-specific PRNT titers ( Fig. 2A) . To compare the levels of robustness of ELISA and PRNT in differentiating between CHIKV and MAYV infection over time, absolute differences between CHIKV and MAYV ELISA reactivities and PRNT titers were calculated for longitudinal CHIKV samples. Differences between CHIKV and MAYV were highest at 5 to 9 dpo for IgM, at 10 to 14 dpo for IgG, and at 90 dpo with PRNT, highlighting the utility of IgM detection in acute infections, IgG detection in early convalescence, and PRNT in late convalescence (Fig. 2B) .
In this study, 20% of all PRNT-positive samples showed cross-neutralization. However, comparing PRNT titers allowed unambiguous classification of all samples (Fig. 2C) . Mean CHIKV-specific and MAYV-specific PRNT titers differed 40-fold for CHIKV samples and 35-fold for MAYV samples (P Ͻ 0.0001, Mann-Whitney test) ( Fig. 2D) .
Parallel PRNT testing for CHIKV and MAYV increased the assays' positive predictive values (PPV) from 80.0% to 100% (P ϭ 0.0053, Fisher's exact test). We thus compared ELISA reactivities of all samples to examine whether parallel ELISA testing allows differentiation of CHIKV-specific and MAYV-specific antibodies. Assuming relatively higher ELISA reactivity to represent the correct result and lower reactivity to represent a cross-reactive test result, parallel testing significantly increased PPV for IgM detection from 35.3% to 88.2% ( Fig. 2E ) and for IgG detection from 61.3% to 96.8% (P Ͻ 0.0001, Fisher's exact test) ( Fig. 2F ).
Discussion. Consistently with preliminary studies which did not focus on the differentiation of individual viruses (9, 13) , we show that the differentiation of CHIKVand MAYV-specific antibodies based on a single ELISA testing is challenging in regions of cocirculation. Particularly, IgM antibodies were highly cross-reactive, highlighting that false-positive results must be expected during patient diagnostics. Interestingly, IgG cross-reactivity was more frequent among MAYV-specific than among CHIKVspecific sera, which is different from the results of studies describing CHIKV-specific antibodies to be more cross-reactive than o'nyong-nyong virus (ONNV, an alphavirus that is genetically closely related to CHIKV)-specific antibodies. Cross-reactivities of antibodies thus require experimental assessments and cannot be foretold (7) . Our results confirmed preliminary data indicating that PRNT is not immune to crossreactivity but that comparing CHIKV-and MAYV-specific PRNT titers provides robust results, allowing differentiation of both (14) . Notably, unambiguous ELISA and PRNT interpretations may be difficult if a person was recently infected by both viruses, a scenario that we could not investigate in our study. However, to what extent potential superinfection exclusion affects CHIKV, MAYV, and other alphaviruses is unclear. Recently, convalescent-phase sera from CHIKV-infected patients were found to crossneutralize MAYV and the antigenically related Una virus at low titers (14) . There is evidence that preexisting CHIKV immunity can also cross-protect from other alphaviruses, including ONNV and the antigenically distant Venezuelan equine encephalitis virus (VEEV) (15) (16) (17) . To overcome the low specificity of ELISA and disadvantages of PRNT, including high workloads, new serologic tests allowing the differentiation of CHIKV-and MAYV-specific antibodies are urgently needed (7) . Structural protein microarrays (18) , in-house ELISAs (19, 20) , and competitive ELISAs, such as those developed before for other alphaviruses (21, 22) , may provide solutions. However, those methods need to be extensively validated before application in routine diagnostics. Parallel ELISAs for both CHIKV and MAYV provide a convenient and robust solution to ensure specific diagnostics and differentiate CHIKV from MAYV infections. Naturally, this approach relies on the usage of comparable antigens at comparable amounts and comparable test protocols, and thus our results cannot be extrapolated to the usage of any given test before validation.
Our study is limited by the absence of samples from areas where CHIKV and MAYV are coendemic and from PCR-confirmed MAYV infections. However, the robustness of our sample classifications is supported by three arguments: (i) about half of the MAYV samples were collected 10 years before CHIKV arrived in the Americas (Table 1 ), (ii) classifications are consistent with serologic test results, and (iii) Peru is a hot spot of MAYV circulation, while CHIKV activity is extremely low (2, 23) .
Our study provides a template that is amenable for usage in public laboratories dealing with large numbers of samples in resource-limited settings in all regions of alphavirus coemergence, such as CHIKV and ONNV in Africa, CHIKV and Sindbis virus in Asia, equine encephalitis viruses in North and Central America, and Ross River virus and Barmah Forest virus in Australia (24) .
